Special Issue "Current State of Immunotherapy for Lung Cancer"
Deadline for manuscript submissions: closed (30 September 2021).
New therapeutic agents continue to expand the use of immunotherapy in the lung cancer setting. The recent publication of influential trials has firmly placed immunotherapy as the standard of care for wild type non-small cell lung cancer (NSCLC) in the first and second line setting in advanced disease and following chemotherapy/radiation in stage lll NSCLC. We hope it soon will be the standard of care in mesothelioma. Evidence in efficacy exists in extensive stage small cell carcinoma and this will be reviewed.
This Special Issue is aimed at all health care providers specializing in the care of patients with lung cancer. The issue provides a thorough summary of the most recent trial results for immunotherapy in the first line setting in advanced disease including trials KEYNOTE-189 and -407 and CheckMate 227 and 9LA. As we integrate immunotherapy into our clinical practice, we need to understand how to select the patients who are most likely to benefit from this therapy. Current and emerging biomarkers will be discussed. Supporting our patients through toxicity management is another practical matter we must consider, and is relevant to all jurisdictions, not just Canada.
Despite our enthusiasm for this treatment option, immunotherapy raises other important issues that need to be discussed, including improving efficacy, decreasing cost, expanding access and evaluating how immunotherapy works in a real world situation. We encourage all contributors, especially authors from other countries, to add their voice and perspectives to the current state of immunotherapy for lung cancer.
Prof. Dr. Barbara Melosky
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.